Brought to you by 
Rexahn enters trial collaboration with Merck for breast cancer tx
25 Oct 2021
Executive Summary
Merck & Co. Inc. and Rexahn Pharmaceuticals Inc. penned an agreement to study the combination of Rexahn’s RX5902 (supinoxin) with Merck’s Keytruda (pembrolizumab) as a potential therapy for metastatic triple negative breast cancer (TNBC).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rexahn enters trial collaboration with Merck for breast cancer tx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice